Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Financial Officer | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,453 |
Ending reported balance
After 2026-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-01 · Exercise / conversion · Acquired 2,375 · Balance 188,130 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 2 · 2026-03-01 · Tax withholding · Disposed 677 · Balance 187,453 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-01 · Exercise / conversion · Disposed 2,375 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 21:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000011 · form4-03032026_040301.xml · derivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 677 | $2.87 | $1,942.99 |
DisclosureSEC source: 0001957554-26-000011 · form4-03032026_040301.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,453 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000011 · form4-03032026_040301.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 22,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000007 · form4-02052026_090243.xml · derivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,075 Underlying: Common Stock · 22,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 6,449 | $3.47 | $22,378.03 |
DisclosureSEC source: 0001957554-26-000007 · form4-02052026_090243.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,755 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:41 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 22,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000007 · form4-02052026_090243.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 23:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 346,800 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001957554-26-000009 · form4-02062026_110245.xml · derivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,800 Underlying: Common Stock · 346,800 shares Expires 2036-02-01 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 23:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 99,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000009 · form4-02062026_110245.xml · derivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,100 Underlying: Common Stock · 99,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000005 · form4-02032026_100245.xml · derivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 14,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 4,984 | $3.51 | $17,493.84 |
DisclosureSEC source: 0001957554-26-000005 · form4-02032026_100245.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,179 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:36 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 14,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000005 · form4-02032026_100245.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 13,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · derivative · entry 9 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 4,461 | $2.88 | $12,847.68 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 6 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,413 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 13,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 5 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · derivative · entry 8 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,250 | $3.01 | $6,772.50 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 4 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,674 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · derivative · entry 7 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025. F3 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 19,934 | $3.01 | $60,001.34 |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,424 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:27 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001957554-26-000003 · form4-01052026_090132.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006494 · form4-03042025_040308.xml · derivative · entry 5 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,375 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006494 · form4-03042025_040308.xml · derivative · entry 4 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 727 | $1.99 | $1,446.73 |
DisclosureSEC source: 0001415889-25-006494 · form4-03042025_040308.xml · nonDerivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,608 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006494 · form4-03042025_040308.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006494 · form4-03042025_040308.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 308,200 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002939 · form4-02042025_040204.xml · derivative · entry 5 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,200 Underlying: Common Stock · 308,200 shares Expires 2035-02-02 F5 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 88,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002939 · form4-02042025_040204.xml · derivative · entry 4 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,100 Underlying: Common Stock · 88,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002939 · form4-02042025_040204.xml · derivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 14,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 5,816 | $2.48 | $14,423.68 |
DisclosureSEC source: 0001415889-25-002939 · form4-02042025_040204.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,860 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 14,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002939 · form4-02042025_040204.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 13,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · derivative · entry 10 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 13,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · derivative · entry 9 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 5,059 | $2.48 | $12,546.32 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 6 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,926 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 13,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 5 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · derivative · entry 8 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F4 · derivative.expiration_date: On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,430 | $2.48 | $6,026.40 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 4 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,785 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · derivative · entry 7 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,750 Underlying: Common Stock · 73,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 30,732 | $2.48 | $76,215.36 |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,715 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000623 · form4-01032025_060106.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 23:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022825 · form4-09042024_100921.xml · derivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vested on September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vested on September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 23:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 286 | $1.18 | $337.48 |
DisclosureSEC source: 0001415889-24-022825 · form4-09042024_100921.xml · nonDerivative · entry 2 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,697 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 23:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022825 · form4-09042024_100921.xml · nonDerivative · entry 1 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · derivative · entry 9 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 427 | $1.24 | $529.48 |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 6 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,983 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 5 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · derivative · entry 8 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · derivative · entry 7 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 677 | $1.24 | $839.48 |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 4 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,910 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 3 Balthaser Kevin · CIK 0001957554 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.